PhRMA Statement on New Hampshire Prescribing Data Legislation

May 11, 2006, 01:00 ET from Pharmaceutical Research and Manufacturers of America

    WASHINGTON, May 11 /PRNewswire/ -- Pharmaceutical Research and
 Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued
 the following statement today regarding New Hampshire House Bill 1346:
     "This legislation, if passed, could result in significant unintended
 consequences that could have an adverse impact on activities aimed at
 enhancing patient care and the appropriate use of medicines. Foreclosing
 all access to prescribing data could also hamper manufacturers' ability to
 alert physicians of important new information about medicines in a timely
     "There are several programs administered by the Food and Drug
 Administration (FDA) that depend on the ability of pharmaceutical companies
 to contact individual physicians. For example, FDA relies on pharmaceutical
 companies to give immediate notice to physicians of new safety information.
 In the event of a drug shortage, an instance of suspected drug
 counterfeiting or tampering, or a drug recall, the federal system depends
 on the ability of the manufacturer of the product to communicate directly
 and promptly with prescribing physicians. Appropriate access to prescribing
 data enables companies to quickly identify and reach out to physicians who
 prescribe the specific products at issue.
     "FDA may also request the manufacturer of a product to implement a
 'risk management plan' to address a certain safety issue. These plans may
 require the pharmaceutical company to monitor prescribing practices and to
 ensure that individual physicians are communicating critical safety
 information to patients. These important efforts would be significantly
 impeded by the legislation if passed.
     "This bill does not address personal medical privacy, which is already
 protected under federal law. Patients should know that when pharmaceutical
 company representatives obtain prescribing data, it does not contain
 individual patient information. We hope Governor Lynch takes these concerns
 into consideration and vetoes this bill."
     The Pharmaceutical Research and Manufacturers of America (PhRMA)
 represents the country's leading pharmaceutical research and biotechnology
 companies, which are devoted to inventing medicines that allow patients to
 live longer, healthier, and more productive lives. PhRMA companies are
 leading the way in the search for new cures. PhRMA members alone invested
 an estimated $39.4 billion in 2005 in discovering and developing new
 medicines. Industry-wide research and investment reached a record $51.3
 billion in 2005.
     PhRMA Internet Address:
     For information on how innovative medicines save lives, visit:
     For information on the Partnership for Prescription Assistance, visit:
     For information on the danger of imported drugs, visit:

SOURCE Pharmaceutical Research and Manufacturers of America